Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib for recurrent glioblastoma
ChiCTR1800014395Phase 2Recruiting
- Sponsor
- Xijing Hospital
- Start
- Nov 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in glioblastoma (GBM), sponsored by Xijing Hospital. Primary endpoints: 6-month progression-free survival rate and Objective response rate. Started Nov 2017; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR1800014395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014395.